Viewing data from:

RASAGILINE MESYLATE

ANDA

RASAGILINE MESYLATE | A201823 | WATSON LABORATORIES INC

2 strengths0 unique patents0 unique exclusivities

Medicare Part D Spending

CMS annual spending data for Rasagiline Mesylate (2023)

Total Spending

$43.9M

Total Claims

142,903

Beneficiaries

30,404

Avg Cost/Unit

$5.34

Spending Trend

$105.4M(2019)→$93.0M(2020)→$66.4M(2021)→$57.5M(2022)→$43.9M(2023)

YoY Change:-23.0%

5yr CAGR:-15.9%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

API Supply Chain14 active DMFs4 inactive

14 active API suppliers hold Drug Master Files for this ingredient.

MATRIX PHARMACORP PRIVATE LTDRASAGILINE MESYLATE

DMF 223662008

AMINO CHEMICALS LTDRASAGILINE MESYLATE

DMF 226672009

PH HEALTH LTDRASAGILINE MESYLATE (NON STERILE BULK DRUG SUBSTANCE)

DMF 227822009

DR REDDYS LABORATORIES LTDRASAGILINE MESYLATE

DMF 234602010

ALKEM LABORATORIES LTDRASAGILINE MESYLATE

DMF 236792010

ORBION PHARMACEUTICALS PRIVATE LTDRASAGILINE MESYLATE (NON STERILE BULK API)

DMF 236872010

TAI HENG INDUSTRY CO LTDRASAGILINE MESYLATE

DMF 241592010

MAPRIMED SARASAGILINE MESYLATE (CODE 50855)

DMF 253662011

EVERLIGHT CHEMICAL INDUSTRIAL CORPRASAGILINE MESYLATE

DMF 256302011

ALIVUS LIFE SCIENCES LTDRASAGILINE MESYLATE

DMF 265992012

MACLEODS PHARMACEUTICALS LTDRASAGILINE MESYLATE

DMF 267062012

MICRO LABS LTDRASAGILINE MESYLATE

DMF 274482013

INDOCO REMEDIES LTDRASAGILINE MESYLATE

DMF 276342013

TORRENT PHARMACEUTICALS LTDRASAGILINE MESYLATE

DMF 306002016

TEVA PHARMACEUTICAL INDUSTRIES LTDInactiveRASAGILINE MESYLATE

DMF 170752004

MEDICHEM MANUFACTURING (MALTA) LTDInactiveRASAGILINE MESYLATE(MED-201593/M)

DMF 236942010

SUN PHARMACEUTICAL INDUSTRIES LTDInactiveRASAGILINE MESYLATE

DMF 237072010

APOTEX PHARMACHEM INDIA PVT LTDInactiveRASAGILINE MESYLATE

DMF 237462010

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (2)

Sort:

#001 — EQ 0.5MG BASE

0 patents0 exclusivities▴

TABLET;ORAL | Approved: Jul 1, 2013

No patent or exclusivity listings for this strength.

#002 — EQ 1MG BASE

0 patents0 exclusivities▾

TABLET;ORAL | Approved: Jul 1, 2013